Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024
Journal of Medical Microbiology · 2025
DOI: 10.1099/jmm.0.002005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2025. Verfasst von Carolina Salgado Pedace und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bacteriology Center, Adolfo Lutz Institute, São Paulo/SP, Brazil. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Infections caused by Mycobacterium abscessus , an environmentally prevalent, rapidly growing mycobacteria, are increasingly frequent in developed countries.
Objective
To analyse the drug susceptibility profiles of M. abscessus isolated in the state of São Paulo from 2008 to 2024.
Methods
Of the 2,402 M . abscessus isolates identified during those 17 years, 558 (23.2%) met the American Thoracic Society’s microbiologic and clinical criteria for drug susceptibility testing (DST), which was performed for five agents – clarithromycin, amikacin, cefoxitin, ciprofloxacin, and doxycycline.
Results
Clarithromycin showed a dramatic increase in resistance phenotype from ≤10% in the early period to 73–90% over the last 8 years. Over half those isolates demonstrated inducible resistance. Resistance to amikacin was found in fewer than 5% of isolates from 2016 to 2021. In 2022, that result increased to 13%, but for 2023 and 2024, it had fallen back to 2%. Over the past decade, cefoxitin DST has reported the majority of isolates as intermediate, a problematic result in M . abscessus group (MAG) infections, which typically require long-term treatment for successful outcomes. Since 2018, the annual susceptibility rate has been ≤18%, and in five of the 7 years, ≤7%. Ciprofloxacin was typically assessed as susceptible from 2009 to 2011, then decreased sharply to ≤20% over the next several years, and since 2018, the rate has been less than 5%. Through the entire study, doxycycline resistance has remained consistently high; in the years since 2018, ≤6% of isolates have been susceptible.
Conclusion
This study demonstrates wide variation among MAG clinical isolates in the frequency of susceptibility, both across different agents and within individual agents over time. These results emphasize the importance of performing high-quality DST on MAG clinical isolates and suggest the need to consider revising the standard panel of drugs tested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bacteriology Center, Adolfo Lutz Institute, São Paulo/SP, Brazil.
- Division of Infectious Diseases, Tufts Medical Center, Boston, MA, USA.
Zitieren
APA
Pedace, C. S., Arbeit, R. D., Dos Santos Simeão, F. C., Gallo, J. F., de Souza, A. R., & Chimara, E. (2025). Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.002005
Vancouver
Pedace CS, Arbeit RD, Dos Santos Simeão FC, Gallo JF, de Souza AR, Chimara E. Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024. Journal of Medical Microbiology. 2025. doi:10.1099/jmm.0.002005
BibTeX
@article{Pedace2025,
author = {Pedace, Carolina Salgado and Arbeit, Robert D and Dos Santos Simeão, Fernanda Cristina and Gallo, Juliana Failde and de Souza, Andréia Rodrigues and Chimara, Erica},
title = {Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024},
journal = {Journal of Medical Microbiology},
year = {2025},
doi = {10.1099/jmm.0.002005}
}
EUVIMED